Genmab Announces Initiation of Share Buy-Back Program

Core Viewpoint - Genmab A/S is initiating a share buy-back program to reduce capital and fulfill commitments under the Restricted Stock Unit program, with a maximum value of DKK 4.0 billion and a repurchase of up to 2.2 million shares [1][9]. Group 1: Share Buy-Back Program Details - The share buy-back program will commence on March 26, 2025, and is expected to conclude by July 10, 2025, unless terminated or suspended by Genmab [2]. - Genmab has engaged Goldman Sachs International to execute the buy-back program, allowing the bank to make independent trading decisions [3]. - The program will adhere to the price and volume conditions set forth in the relevant EU regulations, ensuring compliance with market standards [4][5]. Group 2: Financial and Operational Aspects - Genmab currently holds 2,537,988 treasury shares, representing 3.83% of its share capital, and reserves the right to suspend or terminate the buy-back program at any time [6]. - Weekly announcements will be made regarding transactions conducted under the buy-back program [6]. Group 3: Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics, with a vision to transform the lives of patients with cancer and other serious diseases by 2030 [7]. - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [8].